{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:54:04Z","timestamp":1790855644437,"version":"4.1.0"},"reference-count":113,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s370880","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T08:30:12Z","timestamp":1687249812000},"page":"441-464","source":"Crossref","is-referenced-by-count":13,"title":["Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives"],"prefix":"10.2147","volume":"Volume 16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3086-9017","authenticated-orcid":true,"given":"Trilok","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0268-960X(10)70003-5","volume":"24","author":"Mahindra","year":"2010","journal-title":"Blood Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"Seer.cancer.gov. Cancer stat facts: myeloma; 2022. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed January 8, 2023."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ctrv.2017.03.010","volume":"55","author":"Rasche","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1182\/blood-2021-148543","volume":"138","author":"Sun","year":"2021","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13148-023-01433-9","volume":"15","author":"Roy Choudhury","year":"2023","journal-title":"Clin Epigenetics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1021\/bi048227k","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"ref26","first-page":"8020","volume":"37","author":"Dispenzieri","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref30","unstructured":"GSK. GSK provides update on DREAMM-3 phase III trial for blenrep in relapsed\/refractory multiple myeloma; 2022. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep\/. Accessed January 26, 2023."},{"key":"ref31","unstructured":"Administration USFD. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma; 2020. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed January 26, 2023."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"E451","DOI":"10.1002\/ajh.26728","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"key":"ref34","unstructured":"Compassionate use individual request program for belantamab mafodotin in multiple myeloma 213304: expanded access program for belantamab mafodotin in patients with relapsed\/refractory multiple myeloma who are refractory to a proteasome inhibitor, and an immunomodulatory agent, and an anti-CD38 antibody. Available from: https:\/\/navigator.reaganudall.org\/expanded-access\/expanded-access-request-program-belantamab-mafodotin-gsk2857916-multiple-myeloma. Accessed April 10, 2023."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1182\/blood-2019-128749","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"Wu","year":"2019","journal-title":"Nat Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","volume":"35","author":"Gantke","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"key":"ref46","unstructured":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed January 29, 2023."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"ref50","unstructured":"Guido Lancman KP, Rodriguez C, Richter J, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper163733.html. Accessed April 10, 2023."},{"key":"ref51","unstructured":"MagnetisMM-3: study of elranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one PI, One IMiD and one anti-CD38 mAb. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04649359. Accessed January 29, 2023."},{"key":"ref52","unstructured":"Pfizer\u2019s elranatamab granted FDA breakthrough therapy designation for relapsed or refractory multiple myeloma. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-elranatamab-granted-fda-breakthrough-therapy. Accessed January 29, 2023."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2022-166494","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"key":"ref54","unstructured":"159 efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-Cell Maturation Antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper162440.html. Accessed February 25, 2023."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1182\/blood-2019-126818","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Naresh Bumma JR, Brayer J, Zonder JA, et al. 4555 updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: a phase 1\/2 first-in-human study; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper159969.html. Accessed January 29, 2023.","DOI":"10.1182\/blood-2022-159969"},{"key":"ref57","unstructured":"Regeneron. Linvoseltamab (BCMAXCD3) initial pivotal phase 2 data show clinically meaningful responses in patients with heavily pre-treated multiple myeloma; 2022. Available from: https:\/\/investor.regeneron.com\/node\/27321. Accessed January 29, 2023."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Naresh Bumma JR, Brayer J, Zonder JA, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: a phase 1\/2 first-in-human study; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper159969.html. Accessed April 10, 2023.","DOI":"10.1182\/blood-2022-159969"},{"key":"ref59","unstructured":"ClinicalTrials.gov. A study to assess AMG 701 montherapy, or in combination with pomalidomide, with or without, dexamethasone in subjects with relapsed or refractory multiple myeloma; 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03287908. Accessed February 7, 2023."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-134063","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Wong NB SW, Paris L, Hofmeister CC, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): results from a phase 1 first-in-human clinical study; 2022.","DOI":"10.1182\/blood-2022-159009"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref63","unstructured":"ClinicalTrials.gov. Study of CC-93269, a BCMA x CD3 T cell engaging antibody, in participants with relapsed and refractory multiple myeloma; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486067. Accessed February 8, 2023."},{"key":"ref64","unstructured":"ClinicalTrials.gov. A study of TNB-383B in participants with relapsed or refractory multiple myeloma; 2019."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2022-167008","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Emma Searle HQ, Wong SW, Megala Costa LJ, et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of majesTEC-2, a phase1b, multicohort study; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper159711.html. Accessed April 5, 2023.","DOI":"10.1182\/blood-2022-159711"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9158","volume":"41","author":"Lindsay","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"6644685","DOI":"10.1155\/2021\/6644685","volume":"2021","author":"Lukjanov","year":"2021","journal-title":"J Immunol Res"},{"key":"ref74","unstructured":"FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma; 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed February 11, 2023."},{"key":"ref75","unstructured":"FDA approves first cell-based gene therapy for adult patients with multiple myeloma; 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma. Accessed February 11, 2023."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1182\/blood-2022-159185","volume":"140","author":"Mi","year":"2022","journal-title":"Blood"},{"key":"ref78","unstructured":"Chunrui LM, Di Wang MD, Baijun Fang MD, et al. 3311 updated results of fumanba-1: a phase 1b\/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper166465.html. Accessed February 23, 2023."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood-2021-146518","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2022-160038","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1182\/blood-2022-168610","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2021-147188","volume":"138","author":"Fernandez de Larrea","year":"2021","journal-title":"Blood"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1182\/blood-2022-170686","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2021-146646","volume":"138","author":"Sperling","year":"2021","journal-title":"Blood"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2021-150037","volume":"138","author":"Qu","year":"2021","journal-title":"Blood"},{"key":"ref88","unstructured":"T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple MyelomaClinically relevant abstract; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper159156.html. Accessed February 26, 2023."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2022-157950","volume":"140","author":"Korst","year":"2022","journal-title":"Blood"},{"key":"ref90","unstructured":"ClinicalTrials.gov. Study of bb2121 in multiple myeloma; 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02658929. Accessed February 11, 2023."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"ref94","unstructured":"ClinicalTrials.gov. LCAR-B38M cells in treating Relapsed\/Refractory (R\/R) Multiple Myeloma (LEGEND-2); 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03090659. Accessed February 11, 2023."},{"key":"ref95","unstructured":"Summary basis for regulatory action \u2013 carvykti; 2022. Available from: https:\/\/www.fda.gov\/media\/156999\/download. Accessed February 11, 2023."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Mi JQ, Zhao W, Jing H, et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41(6):1275\u20131284. doi: 10.1200\/JCO.22.00690","DOI":"10.1200\/JCO.22.00690"},{"key":"ref102","unstructured":"ClinicalTrials.gov. A study of LCAR-B38M CAR-T cells, a Chimeric Antigen Receptor T-cell (CAR-T) therapy directed against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1); 2018. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03758417. Accessed February 12, 2023."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"e2228877","DOI":"10.1001\/jamanetworkopen.2022.28877","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref104","unstructured":"Faris Jamal Abu Za\u2019nouneh OA, Schinke C, Thanendrarajan S, et al. Variability of definition of high-risk multiple myeloma in phase III clinical trials; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper158188.html. Accessed April 05, 2023."},{"key":"ref105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","volume":"15","author":"Swamydas","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discovery"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1182\/blood-2021-154025","volume":"138","author":"Reiser","year":"2021","journal-title":"Blood"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","volume":"5","author":"Gazeau","year":"2021","journal-title":"Blood Adv"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1182\/blood-2022-159289","volume":"140","author":"Cao","year":"2022","journal-title":"Blood"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"12683","DOI":"10.1182\/blood-2022-166167","volume":"140","author":"Motais","year":"2022","journal-title":"Blood"}],"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=90592","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=90592","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T08:30:22Z","timestamp":1687249822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/targeting-b-cell-maturation-antigen-in-patients-with-multiple-myeloma--peer-reviewed-fulltext-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":113,"URL":"https:\/\/doi.org\/10.2147\/ott.s370880","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}